Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02242630 · ClinicalTrials.gov registry record · NA
Relationship to Dose of Triamcinolone Acetonide and Methylyprednisolone to Improvement in Subacromial Bursitis
A NA study, sponsored by Keesler Air Force Base Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 61
- Enrollment target
NCT02242630: Completed NA study, sponsored by Keesler Air Force Base Medical Center.
NCT02242630 is a NA study that has completed, run by Keesler Air Force Base Medical Center. The registered enrollment target is 61 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02242630, a NA study, has completed, sponsored by Keesler Air Force Base Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 61 participants
- Enrollment target
Study Summary
It is currently unknown whether or not the improvement in pain and function related to a "steroid shot" for shoulder pain due to subacromial bursitis is important. This study seeks to determine whether 20 mg or 40 mg of either triamcinolone or methylprednisolone significantly affect improvement in shoulder pain 6 weeks after injection.
Primary Outcome
The primary outcome of this study will be to compare the dose and type of intrabursal corticosteroid received to improvements in a functional measure of the shoulder, the QuickDASH. The QuickDASH is a validated questionnaire of shoulder function consisting of 11 questions with a score from 100 (maximal dysfunction) to 0 (no dysfunction). It is expected that improvements will lead to at least a 10 point improvement (minimal clinically important difference)
Interventions
- DRUG Methylprednisolone, 20 mg
- DRUG Methylprednisolone, 40 mg
- DRUG Triamcinolone, 20 mg
- DRUG Triamcinolone, 40 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2014-09 |
| Est. Completion | 2016-03 |
| Phase | NA |
What the finished NCT02242630 record still lists
NCT02242630 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 61 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 4 interventions - of which Methylprednisolone, 20 mg is the first listed.
NCT02242630 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02242630 about?
NCT02242630 is a clinical study titled "Relationship to Dose of Triamcinolone Acetonide and Methylyprednisolone to Improvement in Subacromial Bursitis". It is currently unknown whether or not the improvement in pain and function related to a "steroid shot" for shoulder pain due to subacromial bursitis is important. This study seeks to determine whether 20 mg or 40 mg of either triamcinolone or methylprednisolone significantly affect improvement in s...
What is the current status of trial NCT02242630?
This trial is currently completed. It is a NA study. The enrollment target is 61 participants. The study started on 2014-09. Estimated completion is 2016-03.
What interventions are being tested in trial NCT02242630?
The interventions under investigation include: Methylprednisolone, 20 mg (DRUG), Methylprednisolone, 40 mg (DRUG), Triamcinolone, 20 mg (DRUG), Triamcinolone, 40 mg (DRUG).
Who is sponsoring clinical trial NCT02242630?
This trial is sponsored by Keesler Air Force Base Medical Center, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02242630's enrollment target sits among peer trials
61 1164th of 2000 higher than 837 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04115306 · 61 participants · Phase 1
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
- NCT05070845 · 61 participants · Phase 2
Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia
- NCT05187832 · 61 participants · Phase 1
A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer
- NCT05269316 · 61 participants · Phase 1
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia